BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24399184)

  • 21. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.
    Whittle SL; Hughes RA
    Rheumatology (Oxford); 2004 Mar; 43(3):267-71. PubMed ID: 14963199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Historical overview of the treatment of rheumatoid arthritis with an emphasis on methotrexate.
    Kremer JM
    J Rheumatol Suppl; 1996 Mar; 44():34-7. PubMed ID: 8833049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Landmark papers on the discovery of methotrexate for the treatment of rheumatoid arthritis and other systemic inflammatory rheumatic diseases: a fascinating story.
    Malaviya AN
    Int J Rheum Dis; 2016 Sep; 19(9):844-51. PubMed ID: 27293066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Chatzidionysiou K; Emamikia S; Nam J; Ramiro S; Smolen J; van der Heijde D; Dougados M; Bijlsma J; Burmester G; Scholte M; van Vollenhoven R; Landewé R
    Ann Rheum Dis; 2017 Jun; 76(6):1102-1107. PubMed ID: 28356243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
    Gaujoux-Viala C; Smolen JS; Landewé R; Dougados M; Kvien TK; Mola EM; Scholte-Voshaar M; van Riel P; Gossec L
    Ann Rheum Dis; 2010 Jun; 69(6):1004-9. PubMed ID: 20447954
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics and pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the 2013 update.
    Zhu H; Deng FY; Mo XB; Qiu YH; Lei SF
    Pharmacogenomics; 2014 Mar; 15(4):551-66. PubMed ID: 24624921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with the focus on rheumatoid arthritis. Integration of a systematic literature research with the expert opinion of a large international panel of rheumatologists within the framework of the 3e initiative].
    Tarner IH; Müller-Ladner U
    Z Rheumatol; 2010 May; 69(3):250-2. PubMed ID: 19756660
    [No Abstract]   [Full Text] [Related]  

  • 28. Methotrexate can prevent cardiovascular events in patients with rheumatoid arthritis: An updated meta-analysis.
    Sun KJ; Liu LL; Hu JH; Chen YY; Xu DY
    Medicine (Baltimore); 2021 Feb; 100(7):e24579. PubMed ID: 33607787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study.
    Nash P; Nicholls D
    Int J Rheum Dis; 2013 Dec; 16(6):652-61. PubMed ID: 24382276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methotrexate: a gold standard for treatment of rheumatoid arthritis.
    Shinde CG; Venkatesh MP; Kumar TM; Shivakumar HG
    J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):351-8. PubMed ID: 25322199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Paradigm shift and future perspectives in rheumatoid arthritis].
    Miyasaka N
    Nihon Rinsho; 2013 Jul; 71(7):1141-6. PubMed ID: 23961658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.
    Kapetanovic MC; Nagel J; Nordström I; Saxne T; Geborek P; Rudin A
    Vaccine; 2017 Feb; 35(6):903-908. PubMed ID: 28081972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methotrexate pharmacogenetics in rheumatoid arthritis.
    Brinker RR; Ranganathan P
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S33-9. PubMed ID: 21044431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Folate supplementation during methotrexate therapy for rheumatoid arthritis.
    Morgan SL; Baggott JE
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S102-9. PubMed ID: 21044441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.
    Louthrenoo W; Kasitanon N; Katchamart W; Aiewruengsurat D; Chevaisrakul P; Chiowchanwisawakit P; Dechanuwong P; Hanvivadhanakul P; Mahakkanukrauh A; Manavathongchai S; Muangchan C; Narongroeknawin P; Phumethum V; Siripaitoon B; Suesuwan A; Suwannaroj S; Uea-Areewongsa P; Ukritchon S; Asavatanabodee P; Koolvisoot A; Nanagara R; Totemchokchyakarn K; Nuntirooj K; Kitumnuaypong T
    Int J Rheum Dis; 2017 Sep; 20(9):1166-1184. PubMed ID: 28730640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
    Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
    Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study).
    van Aken J; Heimans L; Gillet-van Dongen H; Visser K; Ronday HK; Speyer I; Peeters AJ; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2014 Feb; 73(2):396-400. PubMed ID: 23334213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triple Oral Therapy Versus Antitumor Necrosis Factor Plus Methotrexate (MTX) in Patients with Rheumatoid Arthritis and Inadequate Response to MTX: A Systematic Literature Review.
    Mary J; De Bandt M; Lukas C; Morel J; Combe B
    J Rheumatol; 2017 Jun; 44(6):773-779. PubMed ID: 28412710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib.
    da Mota LM; Cruz BA; de Albuquerque CP; Gonçalves DP; Laurindo IM; Pereira IA; de Carvalho JF; Pinheiro Gda R; Bertolo MB; Pinto MR; Louzada-Junior P; Xavier RM; Giorgi RD; Lima RA
    Rev Bras Reumatol; 2015; 55(6):512-21. PubMed ID: 26456224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.